Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro,Obinutuzumab, decision type: , therapeutic area: , PIP number: P/0296/2022

Opinion/decision on a Paediatric investigation plan (PIP): Maralixibat chloride, decision type: , therapeutic area: , PIP number: P/0298/2022

Human medicines European public assessment report (EPAR): Beovu, brolucizumab, Wet Macular Degeneration, Date of authorisation: 13/02/2020, Revision: 10, Status: Authorised

Orphan designation: Pomalidomide, Treatment of multiple myeloma, 08/10/2009, Expired

Human medicines European public assessment report (EPAR): Tandemact, pioglitazone,glimepiride, Diabetes Mellitus, Type 2, Date of authorisation: 08/01/2007, Revision: 22, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Humanized monoclonal antibody of IgG1 subtype targeting NRP1, decision type: , therapeutic area: , PIP number: P/0283/2022

Opinion/decision on a Paediatric investigation plan (PIP): Magnesium lactate dihydrate Tramadol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2022

Opinion/decision on a Paediatric investigation plan (PIP): Modakafusp Alfa, decision type: , therapeutic area: , PIP number: P/0282/2022

Opinion/decision on a Paediatric investigation plan (PIP): N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), decision type: , therapeutic area: , PIP number: P/0275/2022

Opinion/decision on a Paediatric investigation plan (PIP): nebivolol (hydrochloride),Amlodipine (besilate), decision type: , therapeutic area: , PIP number: P/0338/2022